Table 3

Comparison of clinical data among groups A-D, between antibodies to citrulline-related epitope (positive and negative), and between antibodies non-related epitope (positive and negative)

Group

Number of patients

Age in years

Duration

Female/Male

RF

CCP

CRP

ESR

A

14

56.1 ± 10.8^a

12.2 ± 9.2

12/2

89.6 ± 116.7

63.3 ± 66.9^c

1.55 ± 1.86

33.2 ± 16.8

B

5

66.6 ± 2.1^a

11.4 ± 5.4

4/1

422.6 ± 574.5

385.6 ± 396.1

0.88 ± 0.79

41.8 ± 23.4

C

6

65.7 ± 7.8

17.2 ± 12.7

6/0

139.3 ± 146.2

63.8 ± 55.5^d

0.97 ± 0.95

38.3 ± 27.9

D

5

61.2 ± 21.0

6.3 ± 5.8

4/1

47.5 ± 47.0

164.0 ± 84.9^{c, d}

1.18 ± 1.48

31.0 ± 19.1

Anti-citrullinated CapZα-1

+(B+C+D)

16

64.6 ± 12.0

11.6 ± 9.2

14/2

199.2 ± 348.5

195.7 ± 253.2

1.01 ± 1.03

37.1 ± 22.9

-(A)

14

56.1 ± 10.8

12.2 ± 9.2

12/2

89.6 ± 116.7

63.3 ± 66.9

1.55 ± 1.86

33.2 ± 16.8

Citrulline-unrelated epitope

+ (C+D)

11

63.6 ± 14.6

11.7 ± 10.9

10/1

97.6 ± 117.8

109.3 ± 84.7

1.06 ± 1.16

35.0 ± 23.4

-(A+B)

19

58.8 ± 10.4

12.0 ± 8.2

16/3

177.3 ± 325.4

148.1 ± 243.7

1.37 ± 1.65

35.5 ± 18.5

Citrulline-related epitope

+ (B+C)

11

66.1 ± 5.7^b

14.3 ± 9.7

10/1

268.1 ± 405.7

210.1 ± 304.2

0.93 ± 0.84

39.9 ± 24.7

-(A+D)

19

57.4 ± 13.7^b

10.7 ± 8.7

16/3

78.6 ± 103.4

89.8 ± 83.2

1.45 ± 1.74

32.6 ± 16.9

^aP < 0.005; ^b,c,dP < 0.05. CapZα-1, F-actin capping protein α-1 subunit; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.

Matsuo et al. Arthritis Research & Therapy 2006 8:R175   doi:10.1186/ar2085